PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
13.53%
Revenue growth similar to MRVL's 14.60%. Walter Schloss would see if both companies share industry tailwinds.
2.69%
Gross profit growth under 50% of MRVL's 12.74%. Michael Burry would be concerned about a severe competitive disadvantage.
-6.51%
Negative EBIT growth while MRVL is at 87.15%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-6.51%
Negative operating income growth while MRVL is at 87.15%. Joel Greenblatt would press for urgent turnaround measures.
22.30%
Net income growth under 50% of MRVL's 116.25%. Michael Burry would suspect the firm is falling well behind a key competitor.
30.00%
EPS growth under 50% of MRVL's 100.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
20.00%
Diluted EPS growth under 50% of MRVL's 133.33%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.92%
Share reduction more than 1.5x MRVL's 1.92%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
3.95%
Diluted share count expanding well above MRVL's 5.58%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-53.46%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-419.88%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
310.99%
10Y revenue/share CAGR above 1.5x MRVL's 166.14%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
310.99%
5Y revenue/share CAGR above 1.5x MRVL's 166.14%. David Dodd would look for consistent product or market expansions fueling outperformance.
335.67%
3Y revenue/share CAGR above 1.5x MRVL's 166.14%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
497.51%
10Y OCF/share CAGR in line with MRVL's 543.89%. Walter Schloss would see both as similarly efficient over the decade.
497.51%
5Y OCF/share CAGR is similar to MRVL's 543.89%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
26.22%
3Y OCF/share CAGR under 50% of MRVL's 543.89%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
151.32%
Below 50% of MRVL's 570.43%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
151.32%
Below 50% of MRVL's 570.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
73.14%
Below 50% of MRVL's 570.43%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
741.63%
10Y equity/share CAGR 1.25-1.5x MRVL's 567.97%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
741.63%
5Y equity/share CAGR 1.25-1.5x MRVL's 567.97%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
680.22%
3Y equity/share CAGR 1.25-1.5x MRVL's 567.97%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.13%
AR growth well above MRVL's 14.27%. Michael Burry fears inflated revenue or higher default risk in the near future.
31.41%
Inventory growth well above MRVL's 29.09%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
5.49%
Similar asset growth to MRVL's 5.88%. Walter Schloss finds parallel expansions or investment rates.
2.70%
BV/share growth above 1.5x MRVL's 1.70%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.11%
We’re deleveraging while MRVL stands at 7.94%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.64%
R&D growth drastically higher vs. MRVL's 12.03%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-2.90%
We cut SG&A while MRVL invests at 0.48%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.